BioCentury | Jun 18, 2015
Distillery Therapeutics

Therapeutics: CD55

...Infectious disease INDICATION: Malaria In vitro studies suggest inhibiting CD55 on red blood cells (RBCs) could...
...library, followed by cell maturation to erythroblast stage and infection with Plasmodium falciparum merozites, identified CD55...
...CD55 expression. Next steps could include identifying and testing anti-CD55 mAbs to treat malaria. TARGET/MARKER/PATHWAY: CD55...
BioCentury | May 1, 2014
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Engineered Nicotiana benthamiana to produce glycosylated IgMs Engineered N. benthamiana could generate glycosylated IgMs to treat human diseases. In engineered N. benthamiana plants lacking plant-specific...
BioCentury | Aug 16, 2010
Company News

Scancell, Cancer Research U.K. deal

...new ImmunoBody vaccines for all immunotherapy indications. The human mAb mimics the complement regulatory protein CD55...
BioCentury | Jun 17, 2010
Distillery Techniques

Technology: Drug delivery

...displaying human CD55 as safe gene transfer vectors In vitro and mouse studies suggest that CD55-expressing...
...CD55 resulted in less complement activation than conventional Ad5 vectors. In mice, injection of the CD55-displaying...
BioCentury | Feb 8, 2010
Company News

CSL, Patrys deal

...binds non-POU domain containing octamer-binding (NONO; NMT55 ). PAT-SC1 is a human antibody that binds CD55...
BioCentury | Oct 12, 2009
Company News

Debiopharm S.A., Patrys deal

...unit. Patrys renamed the compound PAT-SC1 . The human IgM mAb targeting an isoform of CD55...
BioCentury | Jul 2, 2007
Company News

Oxford BioMedica, Viragen, Roslin Institute deal

...cancers. The company also will focus on developing cancer treatments VG102 and VG106, an anti- CD55...
BioCentury | Apr 30, 2007
Strategy

Transforming AstraZeneca

Transforming AstraZeneca Biologics deals Date Company Deal May-06 Cambridge Antibody Buys the 80.8% of Cambridge Antibody it does not already own for 1,320p per share in cash, or £567M ($1B). AZN says CAT will be...
BioCentury | Feb 5, 2007
Strategy

Focusing deal flow

Focusing deal flow Date Partner Deal April 2006 Abraxis Receives co-promotion rights to Abraxis' Abraxane paclitaxel for breast cancer May 2006 Cambridge Antibody Agrees to buy the 80.8% of Cambridge Antibody it does not already...
BioCentury | Oct 23, 2006
Company News

Debiopharm S.A., AstraZeneca deal

Debiopharm granted AZN subsidiary Cambridge Antibody Technology Group plc exclusive worldwide rights to develop and commercialize SC-1 and derivatives to treat gastric cancer. Debiopharm will receive an undisclosed upfront payment and is eligible for milestones...
Items per page:
1 - 10 of 21